Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls

Journal of Clinical Psychopharmacology

Volumn 29, Issue 2, 2009, Pages 117-123

  Ahn, Yong Min ^a   Lee, Kyu Young ^b   Kim, Chul Eung ^c   Kim, Jae Jin ^d   Kang, Dae Yeob ^e   Jun, Tae Youn ^f   Choi, Jin Sook ^g   Chung, In Won ^h   Kim, Se Hyun ^a   Hwang, Samuel S H ^a   Kim, Yong Sik ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Eulji General Hospital   (South Korea)

^c Inha University School of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Yongin Mental Hospital   (South Korea)

^f The Catholic University of Korea   (South Korea)

^g Seoul Medical Center   (South Korea)

^h Dongguk University Ilsan Hospital   (South Korea)

Author keywords

Amisulpride; Healthy control; Neurocognitive function; Practice effect; Schizophrenia patients

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; LORAZEPAM; NEUROLEPTIC AGENT; ZOLPIDEM;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EFFECT SIZE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; TASK PERFORMANCE; UNSPECIFIED SIDE EFFECT; WECHSLER INTELLIGENCE SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE; TIME FACTORS; TRAIL MAKING TEST; TREATMENT OUTCOME; WECHSLER SCALES; YOUNG ADULT;

EID: 67649369293     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31819a6995     Document Type: Article

References (34)

1. Weiss EM, Bilder RM, Fleischhacker WW. The effects of second generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology. 2002;162:11-17.
2. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci. 2004;114:593-611.
3. Tyson PJ, Laws KR, Flowers KA, et al. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Psychiatry Clin Neurosci. 2006;60:473-479.
4. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
5. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
6. Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25:201-222.
7. Bilder RM, Foldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018-1028.
8. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull. 2000;26:119-136.
9. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand. 2000;102:S83YS86.
10. Meltzer HY, McGurk S. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233-255.
11. Wagner M, Quednow BB, Westheide J, et al. Cognitive improvements in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs. amisulpride. Neuropsychopharmacology. 2005;30:381-390.
12. Mortimer AM. How do we choose between atypical antipsychotics? The advantages of amisulpride. Int J Neuropsychopharmacol. 2004;7:S21YS25.
13. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280:83-97.
14. Legangneux E, McEwen J, Wesnes KA, et al. The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J Psychopharmacol. 2000;14:164-171.
15. Goldberg T, Goldman R, Burdick K, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64:1115-1122.
16. Colonna L, Saleem P, Dondey Nouvel L, et al. Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol. 2000;15:13-22.
17. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549-559.
18. Wechsler E. WAIS-R Manual. New York: The Psychological Corporation; 1981.
19. Yeom T-H, Park Y-S, Oh K-J, et al. Korean-Wechsler Adult Intelligence Scale Manual. Seoul, Korea: The Korean Guidance; 1992.
20. Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination. 3rd ed. Iowa City, IA: AJA Associates; 1994.
21. Summerall SW, Timmons PL, James AL, et al. Expanded norms for the Controlled Oral Word Association Test. J Clin Psychol. 1997;53:17-21.
22. Kim HK. Rey-Kim Memory Test. Seoul, Korea: Dosuchoolpan Shinkyungshimli; 1999.
23. Rey A. L'examen Clinique en Psychologie. Paris: Press Universitaire de France; 1964.
24. Rey A. L'examen psychologique dans les cas d'encéphalopathie traumatique. Arch Psychol. 1941;28:286-340.
25. Conners CK. MHS Staff, Conners' Continuous Performance Test for Windows (CPTII). Toronto, Canada: Multi-Health Systems Inc; 2004.
26. Gold S, Arndt S, Nopoulos P, et al. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry. 1999;156:1342-1348.
27. Russell AJ, Munro J, Jones PB, et al. The National Adult Reading Test as a measure of premorbid IQ in schizophrenia. Br J Clin Psychol. 2000;39:297-305.
28. Benedict RH, Zgaljardic DJ. Practice effects during repeated administrations of memory tests with and without alternate forms. J Clin Exp Neuropsychol. 1998;20:339-352.
29. McCaffrey RJ, Cousins JP, Westervelt HJ, et al. Practice effects with the NIMH AIDS abbreviated neuropsychological battery. Arch Clin Neuropsychol. 1995;10:241-250.
30. McCaffrey RJ, Westervelt HJ. Issues associated with repeated neuropsychological assessments. Neuropsychol Rev. 1995;5:203-221.
31. Woods SP, Delis DC, Scott JC, et al. The California Verbal Learning Test - second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms. Arch Clin Neuropsychol. 2006;21:413-420.
32. Beglinger LJ, Ahmed S, Derby MA, et al. Neuropsychological practice effects and change detection in people with schizophrenia. Schizophr Res. 2003;62:191-194.
33. Shapiro DM, Harrison DW Alternate forms of the AVLT: a procedure and test for form equivalency. Arch Clin Neuropsychol. 1990;5:405-410.
34. Weickert TW, Goldberg TE, Marenco S, et al. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology. 2003;28:1491-1500.